Results 311 to 320 of about 326,443 (336)

Abstract HER2-05: HER2-05 Comprehensive genomic characterization of HER2-low breast cancer

Cancer Research, 2023
Abstract Background: About half of all breast cancers exhibit low HER2 expression. Despite lack of ERBB2 amplification, HER2-low tumors respond to trastuzumab deruxtecan (T-DXd), leading to the NCCN recommendation of T-DXd both for patients with HER2+ and HER2-low metastatic breast cancer (MBC).
Paolo Tarantino, Hersh V. Gupta, Melissa E. Hughes, Janet L. Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Y. Li, Ana C. Garrido-Castro, Romualdo Barroso-Sousa, Brittany Bychkovsky, Laura MacConaill, Neal Lindeman, Bruce Johnson, Matthew Meyerson, Sheheryar Kabraji, Rinath Jeselsohn, Xintao Qiu, Rong Li, Henry W. Long, Eric Winer, Deborah A. Dillon, Giuseppe Curigliano, Andrew Cherniack, Sara Tolaney, Nancy U. Lin   +25 more
openaire   +1 more source

Anti-HER2 Radioimmunotherapy

Breast Disease, 2000
HER2/neu is a receptor protein whose overexpression strongly correlates with poor prognosis in breast carcinomas. It is used increasingly as a therapeutic target for breast carcinomas in clinical human trials. In particular, monoclonal antibodies (mAbs) that target HER2/neu have been investigated for therapeutic applications.
M W, Brechbiel, T A, Waldmann
openaire   +2 more sources

Abstract HER2-17: HER2-17 Novel Quantitative HER2 Assay for Determining Dynamic HER2 Expression in the HER2 IHC 0 “Ultra-Low” Setting: Implications for Precision Therapy in HER2- Breast Cancer

Cancer Research, 2023
Abstract Background: The HER2 antibody drug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (T-DXd) significantly improves outcomes over standard chemotherapy in pts with HER2-LOW (IHC 1+ and IHC 2+ FISH-) metastatic breast cancer (MBC).
Emanuel F. Petricoin, Brian A. Corgiat, Joyce O’Shaughnessy, Patricia LoRusso, Kris Weinberg, Justin Davis, Chelsea Gawryletz   +6 more
openaire   +1 more source

Dual HER2-targeted approaches in HER2-positive breast cancer

Breast Cancer Research and Treatment, 2011
Approximately 15-20% of all breast cancers are human epidermal growth factor receptor 2 (HER2) positive, with clinical studies having validated the HER2 receptor tyrosine kinase pathway as an important therapeutic target. Presently, two HER2-targeted therapies are approved by the Food and Drug Administration for treatment of HER2-positive breast cancer:
Eugene R, Ahn, Charles L, Vogel
openaire   +2 more sources

HER2-Blockade beim HER2-positiven frühen Mammakarzinom

Im Focus Onkologie, 2018
Nach den primaren Ergebnissen der Gepar-Quinto-Studie empfahlen die Studienautoren fur Patientinnen mit HER2-positivem operablem oder lokal fortgeschrittenem Brustkrebs, Lapatinib nicht auserhalb von Studien in Kombination mit einer neoadjuvanten Chemotherapie einzusetzen. Die Langzeitergebnisse fuhren nun zu einer differenzierteren Betrachtung.
openaire   +1 more source

HER2/neu ???? ???????????? ?????????????? ?? ???????????? ???? ?????????????????????????????????? ?????? ????????????

2011
?????????????????????? ?????????????????????? ???????? ???????? ?????????????????????????????? ?????????????? ???????????????????????? ?????? ?????? ???????????????????????????????????? ???????? ???????????? ?? ?????????????????????????????? Her2/neu. ???????????????????????????? ?????????????? ?????????????? ?????????????????????????? ?????????????????
Jeffrey S. Ross, Jonathan A. Fletcher
  +8 more sources

HER2-Positive (HER2 +) Breast Cancer

2022
Tinslee Dilday, Elizabeth Yeh
openaire   +1 more source

?????????? ?????????? ?????????????????? ????????????????????, ?????????????????????? ?????????????????? ?????????? ???????????????????? ????????????????, ???????????????? ?? ???????????? ?????? ?????????????? HER2-???????????????????????????? ???????? ???????????????? ????????????

2018
?? ?????????????? ???? ???????????????????????? ?? ?????????????????? ?????????? ?????????? ?????????????????? ???????????????????? ?????? ?????????????????????????? ????????????????????, ?????????? ???????????????? ?????????????? ???????????????????? ???? 30 ???? 90 ??????, ?????????? ???????????????? ?????????? ?????????????????????????? ?????????? ??
openaire   +1 more source

???????? ???????????????????? ???????????????????? ?? ?????????????? ?????????????? ?? ?????????????????????? ?????????????? HER2-?????????????????????? ???????? ???????????????? ????????????

2010
?????????????????? ???????????????????? ?????????????????????? ????????????????????, ???????????????? ?????????????? ???????????????????? ???????? ??? ???????????????????? ?????????????????? ?? ?????????????????????? ?????????????????????????? ?? ?????????????? ?? ?????????????????????? ?????????????? HER2-?????????????????????? ???????? ???????????????
openaire   +1 more source

HER2

European Journal of Cancer, 2000
M.J. Piccart, A. Di Leo, A. Hamilton
openaire   +1 more source